May 24, 2022 / 06:45PM GMT
Rohit Nagendra;UBS;Investment Banking Analyst -
Good afternoon, and welcome to the 2022 UBS Global Healthcare Conference. Thank you for joining us for our conversation with Basilea Pharma. To walk us through this today, we're pleased to have David and Adesh from Basilea. If you have questions during or after the presentation, please feel free to submit them by scanning the QR code provided, and following the presentation, we can dive into those questions.
David, thank you for joining us. The floor is yours.
David Veitch - Basilea Pharmaceutica AG - CEO
Thank you, Rohit. Thank you for inviting us to the conference. So my name, as was said, is David Veitch. I'll go through majority of the presentation. And then at the end, I'll leave my CFO, Adesh Kaul, to go through the financials.
Just for those of you less familiar with Basilea, we're a Swiss biotech company, have been over the last 22 years of our existence in anti-infectors and about 12 years in oncology. That's pertinent because earlier this year, we announced a
Basilea Pharmaceutica AG at UBS Global Healthcare Conference Transcript
Mar 03, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers